Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C
- 1 April 2016
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (4) , 763-765
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatmentJournal of Hepatology, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionNew England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisNew England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionNew England Journal of Medicine, 2015
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology, 2015
- Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated CirrhosisHepatology, 2015
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014